- Conditions
- Developmental and Epileptic Encephalopathy
- Interventions
- gene therapy
- Drug
- Lead sponsor
- Capsida Biotherapeutics, Inc.
- Industry
- Eligibility
- 18 Months to 7 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 4
- States / cities
- Aurora, Colorado • New York, New York • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced May 22, 2026, 4:15 AM EDT